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The  accumulation  of reactive  oxygen  species  leading  to oxidative  damage  and  cell death  plays  an  impor-
tant  role  in  a number  of  neurodegenerative  disorders.  FOXO3a,  the main  isoform  of FOXO  transcription
factors,  mediates  the cellular  response  to oxidative  stress  by regulating  the  expression  of  genes  involved
in  DNA  repair  and  glutamine  metabolism,  including  glutamine  synthetase  (GS).  Immunohistochemical
investigation  of the  population-based  neuropathology  cohort  of  the  Medical  Research  Council’s  Cognitive
Function  and  Ageing  Study  (MRC  CFAS)  demonstrates  that  nuclear  retention  of  FOXO3a  significantly  cor-





GS expression  correlates  with  increasing  Alzheimer-type  pathology  in  this  ageing  cohort.  Our  findings
suggest  that  in  response  to  oxidative  stress,  the  nuclear  retention  of  FOXO3a  in  astrocytes  upregulates
expression  of GS as  a  neuroprotective  mechanism.  However,  the  activity  of GS may  be  compromised
by  increasing  levels  of oxidative  stress  in  the ageing  brain  resulting  in dysfunctional  enzyme  activity,
neuronal  excitotoxic  damage  and  cognitive  impairment.
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1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia
and is pathologically characterised by the extracellular deposi-
tion of -amyloid (A)  protein, intracellular neurofibrillary tangles
(NFT) of hyperphosphorylated tau, neuronal loss and extensive
synaptic changes in the cerebral cortex. Given the currently limited
success of A-based therapies [25], it is likely that the successful




























































2 A. Fluteau et al. / Neurosc
reatment of AD will also include modulation of mechanisms which
rotect against other processes causing neuronal dysfunction and
eurodegeneration, including excitotoxicity and oxidative stress.
haracterisation of these mechanisms is essential to develop novel
europrotective targets aimed at preventing neuronal dysfunction
nd cognitive impairment in the ageing population.
Glial pathology occurs in the ageing brain and is a major con-
ributor to age-related neurodegeneration [26,38]. Astrocytes play
 key role maintaining homeostasis in the CNS, including the uptake
nd recycling of neurotransmitters such as glutamate [20]. Extra-
ellular glutamate levels are mainly regulated through re-uptake
rom the synaptic cleft via glial excitatory amino acid transporters
EAATs) [43]. A functional glutamate-glutamine metabolic cycle
etween astrocytes and neurones is vital for preventing excessive
xtracellular accumulation of the neurotransmitter leading to neu-
onal excitotoxicity [8,11]. Loss of astrocyte-associated EAAT2 and
lutamate excitotoxicity are features of brain ageing and neurode-
enerative diseases, including AD [18,21,36].
Forkhead box class O (FOXO) proteins form a family of tran-
cription factors which are phosphorylated and regulated by Akt,
esulting in their nuclear exclusion and the termination of their
ctivity [42]. Activation of FOXO, depending on cell type, regulates
 wide range of biological processes including stress resistance,
ell cycle regulation, development and ageing [19]. Glutamine
ynthetase (GS), which catalyses the conversion of glutamate to
lutamine, is highly expressed in astrocytes and is transcription-
lly regulated by the phosphoinositide-3-kinase (PI3K)-Akt-FOXO
athway [41]. In contrast to Akt signalling, oxidative stress induces
he nuclear retention of FOXO which, depending on the severity of
he stimulus, results in either apoptosis or a protective response,
ncluding the transcription of anti-oxidant genes and activation of
 DNA damage response [3,15,17,39]. One member of the forkhead
ranscription factors, FOXO3a, has been implicated in a number
f neurodegenerative disorders, including AD [3,29,33,45], motor
euron disease [24], Parkinson’s disease [12] and stroke [13], and
s expressed throughout the cortex and hippocampus [14].
The Medical Research Council’s Cognitive Function and Age-
ng Study (CFAS) is a well characterised prospective, longitudinal,
opulation-based neuropathological study of the aging population
over 65 yrs) [44]. Studies performed on this population-
epresentative cohort we have previously demonstrated a
eduction in EAAT2 expression [36] and down-regulation of the
I3K-Akt pathway by astrocytes associated with increasing levels
f Alzheimer-type pathology [37], and quantitated oxidative stress
nd the associated DNA damage response in this ageing cohort [35].
iven the proposed role of excitotoxicity in age-related neurode-
eneration, we have now investigated the subcellular localisation
f FOXO3a and its correlation with GS expression, astrogliosis and
he DNA damage response in the ageing brain.
. Materials and methods
.1. Human CNS cases
Human autopsy brain tissue was obtained from one centre
f the Medical Research Council Cognitive Function and Ageing
tudy (MRC CFAS) [1,44], following multi-centre research ethics
ommittee (REC) approval (REC Reference number 11/H0308/2).
europathological lesions were assessed as part of the core CFAS
europathology study using a modified protocol from the Consor-
ium to Establish a Registry of Alzheimer’s Disease (CERAD) [23]
wwws.cfas.ac.uk) and Braak neurofibrillary tangle staging [7]. The
ases were categorised into groups representing entorhinal stages
Braak stages 0-II; 30 cases), limbic stages (Braak stages III-IV; 50
ases) and isocortical stages of tangle pathology (Braak stages V-VI;etters 609 (2015) 11–17
17 cases). The mean age of death was  85.6 (SEM 7.4) years. Demen-
tia status at death had been previously determined, based on all
information available for each participant, including algorithmic
(AGECAT) assessment in life, information from death certification
and a Retrospective Informant Interview (RINI) developed by CFAS
[34]. 59 participants had clinical dementia, 37 did not and in 2
cases clinical dementia status was  undetermined. The median post-
mortem delay was 17 h (IQR 10–32 h) and brain pH 6.49 (IQR
6.25–6.75). Formalin-fixed and frozen lateral temporal cortex sam-
ples (superior/middle temporal gyrus, Brodmann areas 22/21) were
available for all cases and were used in the immunohistochem-
istry and western blotting experiments, respectively. The neuronal
and astrocyte DNA damage response (DDR) (H2AX and DNA-PKcs
nuclear immunoreactivity), astrogliosis (GFAP immunoreactivity),
and local measures of AD-type pathology (A and AT8) were pre-
viously assessed in these cases [35,36]. A total of 98 participants
were included in these analyses, where 61 are females.
2.2. Immunohistochemistry
Immunohistochemistry was  performed using a standard avidin-
biotin complex (ABC) method. Sections were deparaffinised,
rehydrated to water and endogenous peroxidase activity quenched
by placing the sections in 0.3% H2O2/methanol for 20 min  at room
temperature (RT). Sections were subjected to antigen retrieval
(0.01 M tri-sodium citrate pH 6.5, pressure cooker). Following incu-
bation with 1.5% normal serum for 30 min  at RT, the sections were
incubated overnight at 4 ◦C with the well characterised, commer-
cially available antibodies against FOXO3a (1:100; AbCam, UK),
or glutamine synthetase (1:500; Millipore, UK). As phosphoryla-
tion of FOXO3a leads to the nuclear exclusion of the transcription
factor and the termination of its activity, we elected to use an anti-
body which was raised against the N-terminus of the protein, as
opposed to an antibody to specifically detect the phosphorylated
form. To visualise antibody binding, the horse-radish peroxidase
avidin biotin complex was used (Vectastain Elite kit, Vector Labo-
ratories, UK) with 3,3′-diaminobenzidine (DAB) as the chromagen
(Vector Laboratories, UK; brown).
To investigate astrocyte association with FOXO3a, dual labelling
with the astrocyte marker GFAP was performed. Following incu-
bation with the avidin-biotin blocking kit (Vector Laboratories,
UK), FOXO3A immunostained sections were incubated overnight
at 4 ◦C with anti-GFAP (1:500; DakoCytomation, UK), followed by
the alkaline-phosphatase-conjugated avidin-biotin complex (Vec-
tastain Elite kit, Vector Laboratories, UK), developed with alkaline
phosphatase substrate 1 (Vector Laboratories, UK; red) and lightly
counterstained with Mayer’s haematoxylin. Negative controls,
either omission of the primary antibody or isotype controls, were
included in every run.
2.3. Quantitative analysis of FOXO3a and GS
Assessment of FOXO3a and GS-specific immunoreactivity was
performed by capturing bright-field microscopic images in 3 adja-
cent 350 m-wide cortical ribbons, consisting of contiguous fields
to cover the total cortical thickness through the apex of the gyrus,
using a x20 objective (Nikon Eclipse Ni-U microscope, Nikon, UK)
and analysed using the Analysis D̂ software (Olympus Biosys-
tems, Watford, UK). For GS, the image was  thresholded and the
immunoreactive area of the field determined per total area exam-
ined. The number of FOXO3a positive pyramidal neuronal nuclei
was determined using a size exclusion of >450 pixels, and the num-
ber of positive glial nuclei determined by subtracting the number of
pyramidal neuronal nuclei from the total number of positive nuclei.
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Fig. 1. Expression of FOXO3a and GS in the lateral temporal cortex. (a) Specific nuclear immunostaining of FOXO3a was associated with cells morphologically resembling




























o-localised with some (arrow), but not all (arrow head) GFAP+ astrocytes. (d) GS w
00  m in (a) and (b), and 50 m in (c) and (d).
.4. Statistical Analysis
As our data was skewed, median and inter-quartile range (IQR)
as used for descriptive analyses. To test if dementia, sex, age or
ost-mortem delay (PMD) were risk factors for GS and/or FOXO3a
uclear retention, linear regressions were used. Spearman’s cor-
elation coefficient (r) was calculated to verify the strength of
orrelations between continuous variables. All tests were 2-tailed.
5% confidence intervals (CI) were calculated for the linear regres-
ion coefficients (). Statistical analyses were performed using
tatistical package STATA, version 12.
. Results
.1. Expression of FOXO3a and GS in the ageing temporal cortex
Specific nuclear immunostaining of FOXO3a was evenly dis-
ributed throughout all layers of the temporal cortex associated
ith cells morphologically resembling neurones and glia, and was
eldom observed in the white matter (Fig. 1a). In a subgroup of
4 cases, faint FOXO3a immunoreactivity was also detected in the
ytoplasmic compartment of cells (Fig. 1b). Dual staining with GFAP
emonstrated association of FOXO3a with astrocytes (Fig. 1c), but
 proportion of FOXO3a+ glia were not GFAP+. GS was  exclusively
ssociated with astrocytes throughout the cohort, predominantly
taining the astrocyte cell body and their primary radiating pro-
esses within the cortex (Fig. 1d).
The median number of FOXO3A+ neurones within the tem-
oral cortex was 28.9 (IQR = 11.4–51.8), FOXO3A+ glia was
6.6 (IQR = 62.6–118.6) and area GS immunoreactivity was  0.5
IQR = 0.23–0.97). Neither GS nor FOXO3a (neuronal or glia
mmunoreactivity) significantly related to age, sex or PMD,clusively associated with cells with an astrocytic morphology. Scale bar represents
but FOXO3a neuronal immunoreactivity did relate to tissue pH
(Table 1).
3.2. GS but not FOXO3a significantly correlates with
Alzheimer-type pathology
Nuclear localisation of FOXO3a in glia significantly correlated
with increased expression of GS (n = 85, r = 0.23, p = 0.035, Fig. 2a).
Increasing levels of GS+ astrocytes did not significantly correlate
with astrogliosis (n = 92, r = 0.15, p = 0.163) but did with global
measures of brain Alzheimer-type pathology (Braak neurofibril-
lary tangle stage) (n = 93, r = 0.23, p = 0.029, Fig. 2b), and with
local measures of AD pathology in the temporal cortex, namely
A (n = 90, r = 0.24, p = 0.020, Figure 2c) and tau area immunore-
activity (n = 89, r = 0.24, p = 0.022, Fig. 2d). In contrast, neither
FOXO3a+ glia nor FOXO3a+ neurones significantly correlated with
Braak stage (n = 89, r = 0.06, p = 0.571; n = 89, r = -0.08, p = 0.437,
respectively), A (n = 86, r = 0.09, p = 0.405; n = 86, r = 0.16, p = 0.142,
respectively), or tau pathology (n = 84, r = 0.14, p = 0.194; n = 84,
r = 0.08, p = 0.482). The number of FOXO3a+ neurones, FOXO3a+ glia,
and GS immunoreactive area (%) within each Braak stage is shown
in Table 2.
3.3. FOXO3a nuclear expression significantly correlates with a
DNA damage response
We investigated the relationships between FOXO3a neuronal
and glial expression with astrogliosis and levels of a DNA damage
response. FOXO3a+ glia did not correlate with astrogliosis (n = 88,
r = 0.09, p = 0.377), but significantly correlated with FOXO3a+ neu-
rones (n = 89, r = 0.68, p < 0.001, Fig. 3b). FOXO3a+ glia correlated
with H2AX+ glia (n = 87, r = 0.23, p = 0.030, Fig. 3c), and FOXO3a+
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Table 1
Linear regression analyses investigating the relationship between GS and FOXO3a (glial or neuronal immunoreactivity) with demographics and brain pH.
 95%CI() p
GS Age 0.01 (−0.01; 0.03) 0.440
pH  −0.12 (−0.46; 0.22) 0.474
PMD  0.00 (−0.01; 0.01) 0.448
Sex  −0.23 (−0.59; 0.12) 0.191
FOXO3a glial Age −0.25 (−1.72; 1.23) 0.741
pH  20.15 (−8.00; 48.29) 0.158
PMD  0.09 (−0.49; 0.68) 0.749
Sex  7.22 (−15.11; 29.56) 0.522
FOXO3a neuronal Age −0.44 (−1.32; 0.44) 0.321
pH  25.16 (8.10; 42.22) 0.004
PMD  -0.16 (−0.52; 0.19) 0.357
Sex  5.30 (−8.07; 18.68) 0.433
Fig. 2. GS expression associates with Alzheimer-type pathology. Increasing GS+ astrocytes associated with (a) FOXO3a+ glia, (b) Braak stage, (c) -amyloid plaques and (d)
levels  of tau (AT8 immunoreactivity).
Table 2
Number of FOXO3A+ neurones, FOXO3A+ glia, and GS immunoreactive area (%) within each Braak group.
Braak group Entorhinal Limbic Isocortical
FOXO3A+ neurones Median (IQR) 31.0 (14.5–58.7) 28.9 (11.9–45.5) 20.2 (9.7–52.3)








GS  Median (IQR) 0.5 (0.1–0.6
QR: inter-quartile range.
eurones significantly correlated with H2AX+ neurones (n = 87,
 = 0.27, p = 0.010, Fig. 3d).
.4. Relationship to dementia statusNeither GS (OR = 2.37, 95%CI (OR) = 0.96; 5.86, p = 0.061),
OXO3a neuronal (OR = 0.99, 95%CI (OR) = 0.98;1.01, p = 0.591)
or FOXO3a glial expression (OR = 1.00, 95%CI(OR) = 0.99; 1.01,0.4 (0.2–1.0) 0.8 (0.3–1.2)
p = 0.279) were significant predictors of dementia when the analy-
ses were controlled for age and sex.
4. DiscussionFOXO transcription factors control various biological functions,
including apoptosis, and the expression of genes involved in the
regulation of glutamine metabolism, DNA repair and resistance to
oxidative stress [4,19,41]. In the present study we  demonstrate that

































ig. 3. FOXO3a expression correlates with a DNA damage response. (a) FOXO3a+ gl
c)  FOXO3a+ glia significantly correlated with H2AX+ glia, while (d) FOXO3a+ neur
uclear retention of FOXO3a significantly correlates with a DNA
amage response and with GS expression by astrocytes, but not
ith Alzheimer-type pathology in the ageing brain. Furthermore,
e show that GS expression correlates with local burdens of A
laques and tau pathology in this ageing cohort.
The generation of reactive oxygen species (ROS) leading to
xidative damage and neuronal cell death plays an important role
n the pathogenesis of neurodegenerative disorders, suggesting
hat anti-oxidant defence mechanisms are unable to cope with
ncreasing ROS levels in these diseases [22]. Glutamate and A
re two oxidative stressors: at high concentrations glutamate ele-
ates intracellular calcium levels and increases the formation of
OS [30]; while A induces mitochondrial dysfunction resulting in
he generation of ROS [2]. FOXO3a, the main isoform of FOXO tran-
cription factors, mediates cellular responses to oxidative stress
nd modulates adaptive responses. Post-translational phosphory-
ation of FOXO3a regulates the translocation of FOXO3a from the
ucleus to the cytosol, resulting in the repression of the tran-
cription of genes associated with protection against oxidative
tress, DNA repair and anti-apoptosis [42]. The redox potential of
eurones and glia is essential to protect against neurotoxic ROS
evels which result in neuronal dysfunction and are associated
ith cognitive impairment. In the present study we demonstrate
ncreased nuclear retention of FOXO3a by neurones and glia signif-
cantly correlates with a DNA damage response suggesting that,
n response to oxidative DNA damage, FOXO3a may  play a key
ole regulating the expression of neuroprotective anti-oxidant
enes.Cognitive decline is associated with synaptic loss and impaired
ynaptic connectivity, which may  occur as a result of impaired neu-
otransmitter recycling and associated neuronal excitotoxicity [27].
e previously showed a reduction in astrocyte expression of thewed no association with astrogliosis, (b) but did correlate with FOXO3a+ neurones.
ignificantly correlated with H2AX+ neurones.
glutamate transporter EAAT2 associated with increasing levels of
Alzheimer pathology, which likely results in the accumulation of
excitotoxic levels of glutamate [36]. Levels of glutamate, the major
excitatory neurotransmitter in the CNS, are primarily regulated
by GS which is expressed by astrocytes in all cortical layers [32].
An increase in GS expression has been reported in the prefrontal
cortex in AD and in the CSF of vascular dementia, motor neu-
ron disease and AD patients [5,9,40]. In support of these findings,
we demonstrate a significant increase in GS expression associated
with increasing levels of Alzheimer-type pathology in the ageing
brain. In contrast, other studies have reported a reduction in the
astrocytic expression of this enzyme in AD which shows no asso-
ciation with A pathology [16,32]. Complicating the interpretation
of these conflicting reports GS is significantly oxidised in both AD
and mild cognitive impairment cases [10], with oxidation signifi-
cantly reducing its activity [31]. Furthermore, while A has been
shown to induce astrocyte expression of GS in vitro [28], proteomic
analysis has identified GS as being susceptible to oxidation after
exposure to A1 – 42 [6]. Our findings suggest that in response to
oxidative stress, the nuclear retention of FOXO3a increases the
expression of GS as a neuroprotective mechanism by astrocytes
to maintain homeostasis of the synaptic environment and protect
against accumulating levels of glutamate and neuronal excitotox-
icity in the ageing brain. However while levels of GS may  rise,
its activity may  be compromised by increasing levels of oxidative
stressors, including glutamate and local A pathology, resulting in
dysfunctional enzyme activity, neuronal excitotoxic damage and
cognitive impairment.
Astrocytes play a key role in maintaining homeostasis within the
synaptic and neuronal environments. Understanding which factors
control and modulate FOXO3a-mediated neuroprotection is crucial
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